Abstract: Retinoblastoma can present in 1 or both eyes and is the most common intraocular malignancy in childhood. It is typically initiated by biallelic mutation of the RB1 tumor suppressor gene, leading to malignant transformation of primitive retinal cells. The most common presentation is leukocoria, followed by strabismus. Heritable retinoblastoma accounts for 45% of all cases, with 80% being bilateral. Treatment and prognosis of retinoblastoma is dictated by the disease stage at initial presentation. The 8th Edition American Joint Committee on Cancer (AJCC) TNMH (tumor, node, metastasis, heritable trait) staging system defines evidencebased clinical and pathological staging for overall prognosis for eye(s) and child. Multiple treatment options are available in 2018 for retinoblastoma management with a multidisciplinary team, including pediatric ocular oncology, medical oncology, radiation oncology, genetics, nursing, and social work. Survival exceeds 95% when disease is diagnosed early and treated in centers specializing in retinoblastoma. However, survival rates are less than 50% with extraocular tumor dissemination. We summarize the epidemiology, genetics, prenatal screening, diagnosis, classification, investigations, and current therapeutic options in the management of retinoblastoma.
R etinoblastoma can present in 1 or both eyes and is considered the most common intraocular malignancy in childhood. The main therapeutic priority for retinoblastoma is to first save the child's life through early tumor detection and prevention of metastatic spread. Secondary goals are globe salvage and maximizing visual potential. With timely intervention while tumors remain small, the survival rate for affected children is nearly 100%. 1 Globally, mortality is considerably higher due to delayed diagnosis, poor access to multidisciplinary retinoblastoma-specific health care and pathology, lack of genetic testing and counseling, and socioeconomic factors. [2] [3] [4] Advanced retinoblastoma can directly invade the orbit, spread via the optic nerve to the central nervous system, or metastasize hematogenously to bone marrow, and later to visceral organs. Late diagnosis is therefore associated with high morbidity and mortality. We predict that improved understanding of retinoblastoma among primary care providers, pediatric ophthalmologists, and parents will enable early diagnosis and timely intervention. With safe, evidence-based new therapeutic approaches to clearly define disease stage, collaborative care with Internet communication specific to retinoblastoma care 3, 5 (http://depictrb.technainstitute.com/), and location of nearby centers for retinoblastoma care worldwide (http://map.1rbw.org/), we would hope that no child should die from retinoblastoma. 3 The yet unaddressed major cause of later death of these children is second primary malignancy.
EPIDEMIOLOGY
Retinoblastoma occurs worldwide at an estimated rate of 1 in 16,000-18,000 live births, with approximately 8000 new cases predicted annually. 3 Mean age at diagnosis is 27 months for unilateral and 15 months for bilateral retinoblastoma in Canada but 36 and 25 months, respectively, in Kenya, where many children present with extraocular disease. 4 There are no ethnic or sexual predilections and no geographic or environmental associations with retinoblastoma.
GENETICS
Retinoblastoma is the prototypic genetic cancer. 1 The tumors have mutation of both copies of the RB1 tumor suppressor gene located on the long arm of chromosome 13 (13q14), which encodes the retinoblastoma protein (pRB). The cellular origin of retinoblastoma is likely a uniquely susceptible cone photoreceptor precursor cell in the infant retina, which remains within the inner nuclear layer after losing both alleles of the RB1 tumor suppressor gene. 3, 6 This initiates a benign precursor, "retinoma," which usually progresses to retinoblastoma with accumulation of increasing genomic changes and uncontrolled cellular proliferation. 7, 8 There are 2 major genetic forms of retinoblastoma: heritable (also known as germline) and nonheritable. Heritable retinoblastoma accounts for 45% of all cases; 80% are bilateral, 15% unilateral, and 5% trilateral (bilateral retinoblastoma with pineal/midline neuroectodermal tumor). 1 One RB1 allele is mutated in all cells and a second somatic mutagenic event affects the remaining allele in a primitive retinal cell (known as the "2-hit model"), thus initiating tumorigenesis. 9 A mutated RB1 allele is inherited in only 5% of children with heritable retinoblastoma. 1 Children of a parent with heritable retinoblastoma have a 45% chance of being affected (50% risk of inheritance and 90% penetrance). However, most heritable retinoblastoma arises de novo and the RB1 mutation may be present in all cells (preconception mutation) or only a subset of cells, termed "mosaicism" (postconception mutation) (Fig. 1) . 1, 10, 11 Most children with retinoblastoma are the first A, Pedigree of a family with a unilaterally affected father discovered to be mosaic (H1) for a high penetrance RB1 mutation when his second child was found to have bilateral retinoblastoma (H1 family member (proband) with the disease. Children with heritable retinoblastoma are usually diagnosed earlier and present with bilateral, multifocal tumors. Frequent examinations under anesthesia (EUA) for retinal examination with scleral indentation are recommended up to at least 3 years of age to treat tumors when they are as small as possible with minimally invasive therapies. 12 Persons with RB1 germline predisposition also have a high lifetime risk of developing second primary malignancies, especially osteosarcomas, soft-tissue sarcomas, and melanomas. [13] [14] [15] Approximately 55% of cases have nonheritable retinoblastoma that is always unilateral. Of nonheritable retinoblastoma, 98% result from somatic loss of both RB1 alleles in a susceptible retinal precursor cell, but 2% have normal RB1 alleles (RB1 +/+ ) and are initiated by somatic amplification of the MYCN oncogene. 16 These tumors are always unilateral, nonheritable, and diagnosed at median 4.5 months.
Genetic testing and counseling are extremely important in the management of retinoblastoma, involving a laboratory with high sensitivity to detect RB1 mutations.
12 RB1 genetic testing of the proband may identify heritability, and at-risk family members may then undergo testing for the specific mutation. Children of a proband with bilateral retinoblastoma have a 50% risk of carrying the RB1 mutation, whereas children of an untested unilateral proband have a 7.5% risk (50% × 15%), which can be accurately updated to either 100% or 0% by genetic testing of the proband and then the fetus if the proband is found to carry an RB1 mutation.
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The frequency of follow-up for children at risk of retinoblastoma is informed by the results of genetic testing and counseling.
PRENATAL SCREENING
Children with a family history of retinoblastoma who carry the RB1 mutation are at risk of tumors at birth. Chorionic villus sampling (between 11-14 weeks' gestation) or amniocentesis (after 16 weeks' gestation) may be considered so parents have choices of how to manage the pregnancy if the fetus has the RB1 mutation. Amniocentesis can also be offered at 33 weeks' gestation when the risks of miscarriage are lower and manageable. 1 Examination for tumors as soon as possible after birth, followed by repeated EUA for the first few years of life, facilitates early detection of tumors that can be managed with less invasive FIGURE 2. The Internet and public media now help with awareness of retinoblastoma. This mother noticed photoleukorcoria when she downloaded pictures from her camera and took her son to the emergency department the next day when Internet searches revealed that it could be something sinister, like retinoblastoma. Once their son was diagnosed, the family wanted to spread the word by contacting media outlets. This Finnish newspaper featured the photoleukocoria photographs of the child in July, which directly resulted in another child being diagnosed with retinoblastoma in September.
A B C D
interventions. 17 Infants who had prenatal RB1 mutation detection followed by early full-term delivery (36-38 weeks' gestation) and coordinated retinal examination had smaller tumors at birth and improved visual outcomes.
DIAGNOSIS
Retinoblastoma most commonly presents with leukocoria (white pupillary reflex), resulting from light reflecting off the tumor causing a "glint," "cat's eye reflex," or other similar descriptions by parents and other people caring for the baby (Fig. 2) . 4, [18] [19] [20] Retinoblastoma must be the key differential diagnosis suspected by the primary care physician or pediatric ophthalmologist when parents report an abnormal "glow" or "squint." Too commonly, the primary physician has forgotten about retinoblastoma and does not react with immediate concern to the observation of the parent, leading to significant delay in diagnosis, despite the strong guidelines for "red reflex" testing as part of routine care.
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Leukocoria is now commonly detected as a white reflection by flash photography, termed "photoleukocoria" (Fig. 2) . 22, 23 Strabismus is the second most common presentation, which occurs with vision loss secondary to central macular involvement. 4, 18, 19 Retinoblastoma may be diagnosed during an office eye examination by a general doctor or pediatrician. All children with high suspicion for retinoblastoma should immediately be referred to a retinoblastoma center for diagnostic confirmation and a staging EUA. 24 This also includes a detailed fundus diagram during dilated indirect ophthalmoscopy with scleral indentation 360 degrees to view the entire retina, documenting the location and size of all tumors relative to the fovea and optic nerve, presence of calcification, subretinal fluid, and vitreous and/or subretinal seeding.
CLASSIFICATION
Treatment and prognosis of retinoblastoma depend on the staging at initial presentation. Tumor size, location, presence of subretinal fluid and/or seeding, and histopathological features are all predictors of overall outcome. A multitude of different classification systems for retinoblastoma has led to significant confusion in the literature, preventing proper comparison among studies and confounding patient care. The International Intraocular Retinoblastoma Classification (IIRC) staged eyes as Group A (very low risk) through E (very high risk). 25 A subsequent modification of Group E); histopathology after enucleation confirmed invasion into the ciliary muscle. G, Unilateral retinoblastoma can mimic advanced Coats disease, particularly in the presence of retinal detachment. This child was initially diagnosed with Coats disease based on total exudative retinal detachment without calcification, but vitreous and subretinal seeding were evident during EUA and retinoblastoma diagnosis was confirmed after enucleation. this classification 26 resulted in severely advanced eyes being classified with less-affected eyes, so that "Group E" no longer was understood to designate eyes in danger of extraocular disease that should be promptly enucleated. 3, 27, 28 The 2017 American Joint Committee on Cancer (AJCC) 8th edition TNMH (tumor, node, metastasis, heritable trait) clinical and pathological staging system is the first evidence-based system for predicting overall prognosis of both eye(s) and patients (Fig. 3, Table 1 ). 29 It is informed by an international survey of 1728 eyes with retinoblastoma comparing all the previous classifications and best separates severity of eye disease and the likelihood to save the eye without use of external beam irradiation; the TNMH has become the gold standard to define the extent of retinoblastoma at diagnosis in 2018.
Small retinoblastoma tumors initially present as round, gray intraretinal lesions (Fig. 3A) . 25 With further growth and expansion of blood supply, the tumor assumes an irregular lobulated shape, opaque white or pink color, and may have areas of calcification (Fig. 3B) . More advanced tumors may have associated vitreous seeding (tumor cells extending beyond the inner limiting membrane into the vitreous cavity) (Fig. 3C ) and subretinal seeding (tumor extension into the subretinal space) (Fig. 3D) , along with exudative retinal detachment (Fig. 3E) .
Advanced retinoblastoma may present with anterior chamber invasion, elevated intraocular pressure with neovascularization, hyphema, vitreous hemorrhage, cataract, or aseptic orbital cellulitis. The most dangerous presentation is aseptic orbital cellulitis, 30 often due to central retinal arterial occlusion at the optic nerve head, causing massive acute tumor and ophthalmic necrosis. 31 Retinoblastoma is importantly the first cancer to recognize the role of germline predisposition by incorporating stage category "H" into the AJCC classification. H1 is supported by the presence of bilateral disease (Fig. 1, Table 1 ), a family history of retinoblastoma, a concomitant central nervous system midline embryonic tumor (trilateral disease), or the presence of high-quality molecular evidence of an RB1 mutation. 29 Those at unknown risk or who have variants of unknown significance are categorized HX. A family member who tests negative for the known RB1 mutation of the proband is considered at population risk (0.007%) and may be assigned H0. If no mutation is found in a proband or an unaffected parent of a proband in a lab with sensitivity exceeding 97% for bilaterally affected patients, the residual risk for undetectable mosaicism is less than 1% and the designation H0* is suggested. 1 Pathological staging (pTNM) can only be performed after enucleation of the affected eye. Features such as massive choroidal invasion (more than 3 mm in largest diameter, or multiple foci of focal choroidal involvement totaling more than 3 mm, or any full-thickness choroidal involvement) (Fig. 4) , retrolaminar invasion of the optic nerve head, scleral invasion, or evidence of extraocular tumor confer high risk for metastases. 29 The presence of such high-risk features (pT3, pT4) warrants metastatic surveillance with cerebrospinal fluid and bone marrow analyses and prophylactic adjuvant systemic chemotherapy.
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INVESTIGATIONS
Diagnosis of retinoblastoma is made clinically and does not rely on histopathology; diagnostic fine needle aspiration biopsy would impose risk of systemic tumor dissemination.
7 B-scan ultrasonography can assess tumor size and calcification, help to distinguish retinoblastoma from other pathologies such as Coats disease and persistent fetal vasculature (PFV), and can be performed with the child awake in the office or at the staging EUA. Wide-field fundus photography with scleral depression to view the entire retina during the staging EUA will document the extent and location of the tumor(s); accurate fundus drawings aid in monitoring response of tumors to treatment that may alter future management.
Handheld optical coherence tomography (OCT) performed on the supine child is valuable in the diagnosis and management of retinoblastoma for localization of the tumor, detection of optic nerve infiltration, evaluation of scars and retinal structure after treatment, and assessment of foveal integrity, which is important to assess visual potential. 34 In a study of 339 OCT sessions, OCT was found to play an important role in confirming (83%) or changing (17%) clinical decisions. 35 Additionally, OCT is extremely helpful in the detection of small invisible tumors that cannot be identified by indirect ophthalmoscopy alone (Fig.  3A) .
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For advanced retinoblastoma, ultrasound biomicroscopy (UBM) is valuable in the precise evaluation of anterior segment and ciliary body extension (Fig. 3F) . In these cases, UBM may provide useful clinical information for management, such as indication for enucleation. 39 Magnetic resonance imaging (MRI) of the brain and orbit is preferred over computed tomography (CT) to evaluate optic nerve and orbital extension and intracranial involvement and to rule out trilateral disease at initial presentation. The use of MRI offers better soft-tissue resolution and avoids the radiation of CT, which increases the risk of second primary malignancy in patients with germline predisposition to cancer because of their RB1 mutation. The diagnostic sensitivity of MRI to detect high-risk features, including postlaminar optic nerve, choroidal, and scleral invasion, is reportedly 59%, 74%, and 88%, respectively. 40 
DIFFERENTIAL DIAGNOSIS
Multiple ocular conditions that present with leukocoria or strabismus may mimic retinoblastoma and may be differentiated by a comprehensive history, clinical exam, and appropriate testing.
Generally, PFV and Coats disease are considered the most common differential diagnoses for unilateral retinoblastoma. 19 Of these, PFV is a sporadic developmental ocular disorder resulting from failure of normal hyaloid vasculature regression. 41 It often presents with leukocoria in the first days to weeks of life. Two thirds of cases are unilateral and may be associated with microphthalmos, retrolenticular fibrovascular mass, elongated ciliary processes, cataract, and a funnel-shaped retinal detachment in advanced cases. A characteristic vascular stalk extending from the optic nerve to the posterior lens capsule is usually noted on clinical exam and/or B-scan ultrasonography.
Coats disease is a rare, unilateral, idiopathic nonhereditary exudative retinopathy presenting most commonly in males during the first or second decade of life. 42 It presents with a "yellow"
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pupillary reflex due to intraretinal and/or subretinal exudation secondary to retinal telangiectasia, often associated with serous retinal detachment (Fig. 3G) . Subretinal lipid deposits can be seen on ultrasonography, and fluorescein angiography shows the classic telangiectatic vessels. Clinically distinguishing Coats disease from retinoblastoma can be challenging in advanced cases with little potential for useful vision. Enucleation is a reasonable diagnostic/treatment option given the life-threatening potential of undiagnosed retinoblastoma. 43 Congenital cataracts may present with leukocoria but the remainder of the ocular exam is usually normal, and B-scan ultrasonography shows no posterior abnormalities. Severe retinopathy of prematurity, incontinentia pigmenti, and Norrie disease may progress to retinal detachment and leukocoria. Infectious causes of leukocoria that can mimic retinoblastoma include ocular toxocariasis and toxoplasmosis, typically in older children with history of soil or contaminated food ingestion or exposure to animals. They typically present with uveitis and posterior or peripheral subretinal granulomas. 17 Other benign tumors such as astrocytic hamartoma and medulloepithelioma are included in the differential diagnosis of retinoblastoma. Myelinated nerve fiber layer, morning glory syndrome, traumatic vitreous hemorrhage, coloboma of the choroid or optic disc, along with photographic artifact from light hitting the optic nerve may also present with leukocoria. However, as retinoblastoma is a potentially life-threatening diagnosis, leukocoria requires urgent referral for full expert fundus examination and diagnosis. 19 Retinoma is not a differential diagnosis for retinoblastoma, as it is on a continuous spectrum of malignancy from benign premalignant to malignant retinoblastoma, and most retinomas indeed progress to malignancy. 7, 8 
MANAGEMENT OPTIONS FOR RETINOBLASTOMA
The primary goal of retinoblastoma management is to save the child's life, followed by salvage of the eye and optimization of visual function. Many treatment options are available and depend on the laterality and extent of disease (Fig. 5) . A multidisciplinary team approach, including 1 or more ophthalmologists focused on care for children with retinoblastoma, pediatric medical oncologist, pediatric radiation oncologist, geneticist, social worker, and others, facilitates optimized care. Retinoblastoma only leads to death when the disease escapes the confines of the eye; delayed diagnosis and treatment and excessive focus on saving a blind eye with advanced disease put the child at risk for extraocular extension, metastases, and death.
Primary enucleation remains the definitive treatment for advanced unilateral retinoblastoma (TNMH 29 cT3 and IIRC 25 Group E eyes), allowing the child to return to normal life and enabling histopathological analysis. 44 For unilateral retinoblastoma, enucleation is the definitive treatment when the optic nerve is not visible and in the presence of retinal detachment (TNMH 29 cT2a and IIRC 25 Group D eyes) or extensive vitreous seeds (TNMH   29   cT2b and IIRC 25 Group D eyes) that otherwise require invasive treatments over several years that are costly to the child and family to save an eye with poor vision. Enucleation is strongly recommended when orbital or optic nerve involvement is suspected, when there is anterior segment invasion, neovascular glaucoma, intraocular hemorrhage, orbital cellulitis, and no potential for useful vision.
The enucleation technique for retinoblastoma minimizes the potential for globe penetration while obtaining 8-12 mm of the optic nerve. Postoperative movement of the prosthesis is better with the myoconjunctival technique of a simple polymethyl methacrylate implant and rectus muscles sutured to the conjunctival fornices than with integrated implants with muscles imbricated to the implant. 45 Attempts to salvage an eye require consideration of staging, visual potential, and considerable discussion with the child's family. Although small tumors may be managed with focal therapies alone, chemotherapy with focal consolidation is required for eyes with tumors too large for primary focal therapy or too close to the optic nerve and macula (TNMH  29 cT1b, cT2 and IIRC   25 Group B, C, D eyes). Chemotherapy can be systemic or, recently, intra-arterial in specific situations. Systemic chemotherapy (most commonly intravenous carboplatin, etoposide, and vincristine) is given over 4 to 6 cycles (every 3-4 weeks) depending on the extent of disease. Chemotherapy reduces tumor size, and focal therapy on repeated follow-up EUAs destroys remnants of tumor (Fig. 6A) . Handheld OCT is excellent to accurately assess tumor activity related to focal therapy scars.
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Intra-arterial chemotherapy (IAC) has an important role in unilateral cT1b and cT2 (IIRC C/D) eyes, but important long-term outcomes, such as visual acuity, extraocular disease, and death,
have not yet been scientifically compared. 46 Characteristically the choroid shows changes after IAC (Fig. 6C) , so the lifelong vision outcome will not be known until there is long-term follow-up and will best be determined by prospective studies. Intra-arterial chemotherapy is excellent for children with unilateral retinoblastoma [cT1b/cT2 (IIRC Groups B/C/D) eyes (Fig. 6B) ] when the optic nerve and fovea are visualized at presentation so there is no risk of masking high-risk features for extraocular extension. The most commonly used intra-arterial chemotherapeutic agent is melphalan, sometimes combined with topotecan and/or carboplatin. Although IAC reportedly has high rates of globe salvage (66% of all eyes and 57% with advanced disease), the literature is limited by variable staging schemes, absence of defined drug protocols, and lack of long-term follow-up data. 46 For well-selected patients, the outcomes of IAC to eradicate the cancer efficiently are impressive. 47 Systemic and ocular complications are uncommon. Systemic complications include unsuccessful catheterization, stroke or a neurological complication (rare), groin hematoma, fever, neutropenia, bronchospasm, nausea, and vomiting. Ocular complications include central retinal artery occlusion, optic atrophy, extraocular muscle dysfunction, retinal detachment, vitreous hemorrhage, ptosis, enophthalmos, and phthisis bulbi. Transient periorbital edema and loss of eyelashes may also be observed. Incompletely reported are extraocular tumor and metastasis.
Focal therapies include laser photocoagulation (Fig. 6 ) and cryotherapy. 48 Laser photocoagulation involves argon laser indirect (532 nm) and transpupillary indirect or transcleral diode (810 nm) laser to first destroy the tumor blood supply, then direct treatment on the regressing tumor. Laser treatment is best given after chemotherapy is completed, as it cuts off the access of chemotherapy to the tumor. Optical coherence tomography has greatly improved the accuracy of laser treatment and minimized local complications, by both discovering tiny tumors invisible to direct viewing with indirect ophthalmoscopy or cameras (Fig.  3A) and accurately identifying residual or recurrent tumor.
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Cryotherapy with a triple freeze-thaw technique for small and recurrent peripheral tumors directly kills tumor cells. A single cryotherapy freeze in peripheral retina 24-48 hours before systemic chemotherapy (prechemo cryotherapy) disrupts the blood-retina barrier and increases penetration of chemotherapy. 49 Vitreous seeds are generally resistant to systemic and intraarterial chemotherapy mainly due to the avascular nature of the vitreous. Intravitreal chemotherapy (melphalan and/or topotecan) is used to control vitreous seeds, previously the most difficult form of intraocular retinoblastoma to cure. 50, 51 The technique involves an anterior chamber paracentesis or ocular massage to reduce intraocular pressure, followed by intravitreal injection under microscopic visualization, with 3 cycles of freeze-thaw cryotherapy at the injection site after needle removal. Intravitreal melphalan injection can be repeated monthly depending on the clinical response. The main complications include vitreous hemorrhage, retinal tears/detachment, damage to the lens leading to cataract, and endophthalmitis. Focal retinal pigment epithelial changes reflect direct retinal toxicity when the drug is not well dispersed through the vitreous. 52, 53 A recent retrospective study of intravitreal chemotherapy injections in 10 retinoblastoma treatment centers worldwide found no extraocular extension of tumor when used with precautions, such as selection of eyes where the source of seeds is controlled, preinjection lowering of intraocular pressure, and postinjection cryotherapy to the needle and needle track. 50, 51, 54 External beam radiotherapy is now only considered as a last resort salvage option for eyes with tumors refractory to all other therapies. Radiation increases the risk of second primary malignancy with standardized incidence ratio of 20.4 for radiotherapy, increasing to 26.4 when radiation was combined with alkylating chemotherapy 55 in H1 29 patients. Although proton beam radiation 56 and stereotactic radiation 57, 58 intend to reduce radiation doses to normal tissues, they still may carry risk for second primary malignancy. 59 Other local long-term adverse effects of radiation include health of soft tissues and bone around the eye, cataract formation, and keratoconjunctivitis sicca. 60, 61 Brachytherapy is focal therapy using a radioactive source (iodine-125, ruthenium-106) applied externally to the eye to A B C treat specific localized intraocular tumors. 58, 62, 63 The radioactive plaques are shielded to minimize radiation exposure to bone, and there is no evidence of risk to increase second primary malignancy. 64 The adverse effects of plaque radiotherapy are local, including cataract, glaucoma, and radiation retinopathy.
The most recent addition to the treatment choices through the long course of therapies to save an eye from retinoblastoma is pars plana vitrectomy (PPV). Previously, opening an eye with active tumor was considered heresy! Now, after vitreous seeds are uncontrolled by main-line therapies, PPV with melphalan in the irrigation fluid is shown to be an effective option without evidence of extraocular disease. 65 However, PPV is reserved for eyes with no evidence of optic nerve involvement both clinically and on neuroimaging, in which case enucleation is the safest option. In patients who are candidates for PPV, a laser barrier around the solid tumor source of seeds can be applied before the planned PPV, with endolaser reinforcement and silicone oil tamponade at the time of PPV to stabilize the retina.
CONCLUSIONS
Our current effort should aim to achieve a near to zerodeath cancer in retinoblastoma within the next 10 years. This can be potentially achieved through improved understanding of retinoblastoma among primary care providers, pediatric ophthalmologists, parents, and the public. Early diagnosis and timely intervention is key to improved overall survival of patients with retinoblastoma. Optimal management of retinoblastoma is multidisciplinary, including the ophthalmologist(s) focused on retinoblastoma, medical and radiation oncologists, geneticists, nurses, social workers, psychologists, and so on. Initiatives such as national tumor board rounds and DePICT RB visualization (demo at http://depictrb.technainstitute.com/) 3, 5 to support communication across the whole management team, including parents, aim to maximize the understanding of retinoblastoma from both clinical and research perspectives and maximize opportunities for patients.
